Review of comorbidities and risk factors for the development of migraine complications (infarct and chronic migraine)

Cephalalgia

Volumn 29, Issue SUPPL. 3, 2009, Pages 7-14

  Dodick, D W ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chronic migraine; Comorbidities; Migraine complications; Migraine review; Migrainous infarct; Risk factors

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANALGESIC AGENT; BARBITURIC ACID DERIVATIVE; CAFFEINE; DIPEPTIDYL CARBOXYPEPTIDASE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; ORAL CONTRACEPTIVE AGENT; VON WILLEBRAND FACTOR;

ALLERGY; ANALGESIC AGENT ABUSE; ANEURYSM; ANXIETY DISORDER; ARTICLE; ASTHMA; ATRIAL SEPTAL ANEURYSM; BIPOLAR DISORDER; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL ASSESSMENT; COMORBIDITY; DEPRESSION; DISABILITY; DISEASE COURSE; DRUG ABUSE; ENDOTHELIAL DYSFUNCTION; EPILEPSY; GENE DELETION; GENETIC POLYMORPHISM; GILLES DE LA TOURETTE SYNDROME; HEART INFARCTION; HYPERTENSION; INFARCTION; ISCHEMIA; MIGRAINE; MIGRAINE WITH AURA; MITRAL VALVE PROLAPSE; OBESITY; PANIC; PATENT FORAMEN OVALE; QUALITY OF LIFE; RAYNAUD PHENOMENON; RETINOPATHY; RISK FACTOR; RISK REDUCTION; SEX RATIO; SLEEP APNEA SYNDROME; SMOKING CESSATION; SNORING; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSFORMED MIGRAINE; WHITE MATTER;

BRAIN ISCHEMIA; CHRONIC DISEASE; COMORBIDITY; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; RISK FACTORS;

EID: 73949148987     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2009.02028.x     Document Type: Article

References (48)

1. Bigal ME, Lipton RB. The prognosis of migraine. Curr Opin Neurol 2008 21 : 301 308.
2. International Classification of Headache Disorders, 2nd edn. International Headache Society 2003-2005. [WWW document]. URL http://ihs-classification.org/en/
3. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008 48 : 1157 1168.
4. Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in women. JAMA 2006 296 : 283 291.
5. MacClellan LR, Giles W, Cole J, Wozniak M, Stern B, Mitchell BD, Kittner SJ. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke 2007 38 : 2438 2445.
6. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 2005 330 : 63 5.
7. Kurth T, Schürks M, Logroscino G, Gaziano JM, Buring JE. Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. BMJ 2008 337 : a636.
8. Colson NJ, Lea RA, Quinlan S, Griffiths LR. The role of vascular and hormonal genes in migraine susceptibility. Mol Genet Metab 2006 88 : 107 113.
9. Dodick DW. Examining the essence of migraine - is it the blood vessel or the brain? A debate. Headache 2008 48 : 661 667.
10. Vargas BB, Dodick DW, Wingerchuk DM, Demaerschalk BM. Migraine with and without aura and risk for cardiovascular disease. Curr Atheroscler Rep 2008 10 : 427 433.
11. Lee ST, Chu K, Jung KH, Kim DH, Kim EH, Choe VN et al. Decreased number and function of endothelial progenitor cells in patients with migraine. Neurology 2008 70 : 1510 1517.
12. Kruit MC, van Buchem MA, Hofman PA, Bakkers JT, Terwindt GM, Ferrari MD, Launer LJ. Migraine as a risk factor for subclinical brain lesions. JAMA 2004 291 : 427 434.
13. International Headache Society Taskforce. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. Cephalalgia 2000 20 : 155 156.
14. American College of Obstetricians and Gynecologists (ACOG). ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. NO. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006 107 : 1453 1472.
15. rd ed. Geneva : Department of Reproductive Health and Research, WHO 2004.
16. Apkarian AV. Cortical pathophysiology of chronic pain. Novartis Found Symp 2004 261 : 239 245.
17. Schmitz N, Admiraal-Behloul F, Arkink EB, Kruit MC, Schoonman GG, Ferrari MD, van Buchem MA. Attack frequency and disease duration as indicators for brain damage in migraine. Headache 2008 48 : 1044 1055.
18. Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003 106 : 81 9.
19. Katsarava Z, Schneeweiss S, Kurth T, Kroener U, Fritsche G, Eikermann A et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004 62 : 788 790.
20. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004 55 : 19 26.
21. Moulton EA, Burstein R, Tully S, Hargreaves R, Becerra L, Borsook D. Interictal dysfunction of a brainstem descending modulatory center in migraine patients. PLoS ONE 2008 3 : e3799.
22. Klapper J, Lucas C, Røsjø Ø, Charlesworth B ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia 2004 24 : 918 924.
23. Winner P, Landy S, Richardson M, Ames M. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. Clin Ther 2005 27 : 1785 1794.
24. Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia 2005 25 : 735 742.
25. Mathew NT, Kailasam J, Meadors L. Early treatment of migraine with rizatriptan: a placebo-controlled study. Headache 2004 44 : 669 673.
26. Goadsby PJ, Zanchin G, Geraud G, de Klippel N, Diaz-Insa S, Gobel H et al. Early vs. non-early intervention in acute migraine - 'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 2008 28 : 383 391.
27. Mathew NT, Finlayson G, Smith TR, Cady RK, Adelman J, Mao L et al. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache 2007 47 : 189 198.
28. Freitag FG, Finlayson G, Rapoport AM, Elkind AH, Diamond ML, Unger JR et al. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS). Headache 2007 47 : 519 530.
29. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007 68 : 343 349.
30. Dodick DW, Silberstein SD. Migraine prevention. Pract Neurol 2007 7 : 383 393.
31. Silberstein SD, Dodick D, Freitag F, Pearlman SH, Hahn SR, Scher AI, Lipton RB. Pharmacological approaches to managing migraine and associated comorbidities - clinical considerations for monotherapy versus polytherapy. Headache 2007 47 : 585 599.
32. Andrasik F, Buse DC, Grazzi L. Behavioral medicine for migraine and medication overuse headache. Curr Pain Headache Rep 2009 13 : 241 248.
33. Scher AI, Stewart WF, Lipton RB. Caffeine as a risk factor for chronic daily headache: a population-based study. Neurology 2004 63 : 2022 2027.
34. Zwart JA, Dyb G, Hagen K, Svebak S, Stovner LJ, Holmen J. Analgesic overuse among subjects with headache, neck, and low-back pain. Neurology 2004 62 : 1540 1544.
35. Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology 2008 71 : 1821 1828.
36. Scher AI, Stewart WF, Lipton RB. The comorbidity of headache with other pain syndromes. Headache 2006 46 : 1416 1423.
37. Bigal ME, Liberman JN, Lipton RB. Obesity and migraine: a population study. Neurology 2006 66 : 545 550.
38. Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology 2006 67 : 252 257.
39. Bigal ME, Tsang A, Loder E, Serrano D, Reed ML, Lipton RB. Body mass index and episodic headaches: a population-based study. Arch Intern Med 2007 167 : 1964 1970.
40. Bigal ME, Lipton RB, Holland PR, Goadsby PJ. Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology 2007 68 : 1851 1861.
41. Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ. The anti-migraine 5-HT (1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol 2001 133 : 1029 1034.
42. Lipton RB. Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology 2009 72 (5 Suppl. S3 7.
43. Jennum P, Hein HO, Suadicani P, Gyntelberg F. Headache and cognitive dysfunctions in snorers. A cross-sectional study of 3323 men aged 54 to 74 years: the Copenhagen Male Study. Arch Neurol 1994 51 : 937 942.
44. Scher AI, Lipton RB, Stewart WF. Habitual snoring as a risk factor for chronic daily headache. Neurology 2003 60 : 1366 1368.
45. McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain 2004 111 : 77 83.
46. Juang KD, Wang SJ, Fuh JL, Lu SR, Su TP. Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes. Headache 2000 40 : 818 823.
47. Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache 2003 43 : 336 342.
48. Tietjen GE, Peterlin BL, Brandes JL, Hafeez F, Hutchinson S, Martin VT et al. Depression and anxiety: effect on the migraine-obesity relationship. Headache 2007 47 : 866 875.